Background and Purpose: Early hematoma growth (EHG) occurs in about one third of patients with
Introduction
Spontaneous intracerebral hemorrhage (sICH) accounts for 10 to 20% of all strokes,with a high rate of mortality and morbidity among survivors of the acute phase. 1 Early hematoma growth (EHG) occurs in about 20-40% of sICH patients and is amajor determinant of early deterioration and poor clinical outcome. 2, 3 Improving our knowledge of the mechanisms underlying EHG could reveal a biochemical marker and helping to discover novel therapeutic targets.
Inflammation is a major feature of pathology associated with sICH. [4] [5] [6] [7] Increased levels of peripheral inflammatory markers on admission,such as fever,elevated white blood cell count (WBC), interleukin-6 (IL-6) and fibrinogen are associated with worse short term outcomes. 4, 5, 7 C-reactive protein (CRP) is an acute-phase reactant induced by IL-6 and is associated with worse outcomes at 1-3 months, [15] [16] [17] but the relationship between CRP and EHG and short-term outcome is unknown.
The aim of this prospective, multicentre study was to assess the sensitivity,specificity,and predictive value of CRP for predicting EHG, early neurological worsening (ENW) and mortality after sICH.
Patients and Methods
We included patients recruited to aprospective,international,multicenter, observational, collaborative registry between January 1,2009 and December 31,2011 (Supplemental file Appendix). 8, 9 Patients aged ≥18 years presenting with aprimary or anticoagulant-associated sICH [defined as sudden intraparenchymal bleeding, confirmed by CT scan, in absence of secondary causes (e.g. brain tumors,vascular malformation,trauma)] were eligible for entry. All patients had baseline clinical data recorded,including demographics,risk factors,co-morbidities, examination findings,Glasgow Coma Scale(GCS) after resuscitation, Hemphill's ICH (oICH) score, 10 routine laboratory panels,and CT scan findings.Data are regularly uploaded from participating centers toacentral database, maintained by the statistical center (Sulmona,Italy).
In the present analysis,we included patients that had presented within six hours of onset, with plasma CRP assay at study entry and complete clinical and imaging data.Patients with a history ofacute or chronic infection(s) in thefour weeks beforesICH,clinical evidence ofacute infection at admission,other concurrent co-morbidities associated with CRP increase, or where surgery was performed before follow-up CT, were excluded to avoid confounding influences (Figure e1 ). TheCRP analysis was performed locally using high-sensitivity immunoturbidimetric assays,with similar performance characteristics, as previously reported.
11
Standard clinical care was based on theguidelines oftheStrokeCouncil oftheAmerican Heart Association 12
and European Stroke Initiative. 13 Informed consent was obtained from all participants or legal representatives and the protocol was approved by local Institutional Review Boards.
Theinitial non-contrast CT scan was reviewed to indentify sICH location (basal ganglia, thalamic, lobar, pontine, cerebellar,or other), hematoma volume (ABC/2 method),midline shift (>10 mm by measuring thedisplacement oftheseptum pellucidum from themidline),and intraventricular extension (IVH;graded by Graeb score). 14 All patients underwent asecond CT scan at 24 hours,or earlier if clinically indicated. CT scans were analyzed blinded to clinical information to prevent bias.
The interobserver reliability of the ABC/2 method and Graeb score were evaluated by comparing measures in arandom sample of 19 scans by local investigators and an independent observer (AP-J).
The primary outcome was EHG,defined as an absolute growth >12.5 cm 3 or relative growth >33%
between the initial and follow-up CT. 3, 15, 16 The primary analysis was the relationship between EHG and CRP. Secondary outcomes included ENW and 30-day mortality.ENW was defined as ≥3 point decrease in the GCS score for non-comatose patients (GCS>8), or ≥2 point decrease for comatose patients (GCS≤8), or the presence of anew neurological deficit, or worsening of previous deficit, or the appearance of clinical signs of brain herniation. 17 Thecause ofdeath was determined from available medical records.Functional outcome was assessed using the Glasgow Outcome Scale (GOS),categorized as good (GOS 4-5) or poor (GOS 2-3).
To establish acut-off point for CRP,centiles obtained at admission and the corresponding rates of EHG and ENW were compared using receiver operator characteristic (ROC) curves. was applied to survival analysis. Eleven patients had missing clinical outcomes, and they were censored, since we knew their survival status at the time of hospital discharge. Statistical analyses were undertaken using SPSS 18.0 (IBM SPSS Software). Median CRP was 9.0 mg/l (IQR:4-16 mg/l).The correlation between log CRP and delay from symptom onset to blood sampling was 0. (Table e1) .Globally,sensitivity was higher than specificity, while for smaller hematoma volumes, specificity was higher than sensitivity. The derivation cohort identified the best cut-off for absolute growth at >10 mg/l (sensitivity 69%,specificity 60%), which produced sensitivity of 90% and specificity of 72% in the validation cohort.
Results

Two
Since there was no difference in median time from baseline to follow-up CTin either CRP group (P=0.525),and CRP>10 mg/l was not more common when samples were taken later (181-360 min from onset; P=0.0525),we did not stratify by delay-to-plasma collection or to imaging time. A CRP>10 mg/l was not significantly more common with anticoagulant use,but was associated with amore severe clinical presentation,defined by lower GCS and higher oICH scores,and with higher blood glucose concentration and WBC count at admission ( Table 1) .EHG and ENW were significantly more frequent in the CRP>10 mg/l group than in CRP≤10 mg/l group. Mortality at 30 days was significantly greater in the CRP>10 mg/l group ( Table 1) and Kaplan-Meier analysis revealed the difference occurred primarily within the first week (Figure 3) .
Univariate analysis revealed significant associations between both EHG and ENW with anticoagulant use,baseline sICH volume and midline shift ( 
Discussion
This study demonstrates that higher plasma CRP within the first few hours of sICH onset was highly predictive of both EHG and ENW.It was also more frequently associated with larger hematoma volume, more severe clinical presentation,the presence of IVH,and death at follow-up. Several points deserve mention.First,the presenting hematoma volumes in the CRP>10 mg/l patients (median 25 cm ).Because hematoma volume at admission predicts both hematoma expansion and poor clinical outcome, 7, 10 one could hypothesize that CRP is asurrogate marker of hematoma volume. However, CRP remained an independent predictor of EHG when corrected for initial hematoma size. Second, the neuroradiological variables assessed in this study reduced the association between CRP and EHG to some extent,suggesting that other clinical and radiological variables could have arole and modify the degree of reported association.Leukoaraiosis,cerebral microbleeds,or brain atrophy,and previous stroke lesions were not specifically measured.However,plasma CRP concentration has been shown to be strongly associated with each of these pathologies, [19] [20] [21] [22] so CRP could represent amarker of vascular risk and advanced biological ageing.It will therefore be important to test these other imaging markers for their associations with EHG and their interaction with the CRP concentration and validate our findings independently.
These results support our previous finding that higher acute plasma CRP is associated with poor outcome and higher mortality at 30-days. 8, 9 This is consistent with aprevious study which demonstrated a significant association between plasma IL-6,the major inducer of CRP,and EHG after ICH. 5 The association between IL-6 and ENW was not reported in that study,but other markers of inflammation,including early fever,high WBC and high fibrinogen did predict neurological decline up to 48h after admission in adifferent analysis of the same cohort. 7 In another study,IL-6 did not predict longer term outcomes. 4 EHG is an important therapeutic target in sICH and accurately discriminating between those at high and low risk of EHG allows potential treatments to be targeted towards those most likely to benefit.This strategy is employed in ongoing studies which use the 'spot sign', defined by the identification of one or more foci of contrast enhancement within an acute primary parenchymal hematoma on the source images of aCT angiogram (CTA), 23 to select patients to receive haemostatic therapies. However,in arecent observational study, 23 the association with risk of hematoma expansion was less with the spot sign (adjusted risk ratio:2.3; 95%CI:1.6-3.1) than we report here for CRP>10 mg/l (adjusted OR:4.7; 95%CI:2.8-8.1).Although amodel combining both the spot sign and CRP may improve prediction of EHG,measurement of CRP using point-of-care methods has advantages over aCTA,in that it can be easily implemented with lower cost,caries no risk (unlike the radiation dose and risks of iodinated contrast in CTA),and does not require specific expertise to interpret.Rapid measurement of CRP concentrations,shortly after onset in sICH,may therefore be amore practical means of discriminating between those at high and low risk of EHG. 
The mechanisms underlying our observations are not fully understood,but warrant further consideration. Apart from activating microglia and complement C3, 24 CRP can directly cause bloodbrain barrier disruption and brain edema formation. 25 Experimental studies demonstrate that an acute local inflammatory response to the hematoma can occur within 1 hour of onset, 26 and asystemic state of inflammation is triggered. 
